KYSE-70

KYSE-70

Cat.No.: CSC-C0414

Species: Homo sapiens (Human)

Source: Esophagus

Morphology: epitheloid cells growing adherently in monolayers

Culture Properties: monolayer

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-C0414
Description
Established from the poorly differentiated invasive esophageal squamous cell carcinoma resected from middle intra-thoracic esophagus of a 77-year-old Japanese man prior to treatment (depth of invasion was not beyond the muscularis propria)
Species
Homo sapiens (Human)
Source
Esophagus
Recommended Medium
Culture Properties
monolayer
Morphology
epitheloid cells growing adherently in monolayers
Karyotype
Human hypotriploid karyotype with 8% polyploidy - 60(54-63)<3n>XXX, -Y, -2, -3, -3, -4, -6, +7, -8, -9, -10, -13, -14, -15, -16, -16, -16, -17, -18, -18, -21, -22, +10mar, del(X)(q25), add(1)(p11), add(2)(q33), del(2)(q33), del(3)(q13), add(4)(q35), add(5
Disease
Esophageal Squamous Cell Carcinoma
Quality Control
Mycoplasma: contamination was eliminated with Ciprobay (ciprofloxacin), then negative in DAPI, microbiological culture, RNA hybridization, PCR assays
Immunology: cytokeratin +, cytokeratin-7 -, cytokeratin-8 +, cytokeratin-17 -, cytokeratin-18 +, cytoker
Storage and Shipping
Frozen with 70% medium, 20% FBS, 10% DMSO at about 2-4 x 10^6 cells/ampoule; ship in dry ice; store in liquid nitrogen
Synonyms
KYSE 70; KYSE70; Kyse70; KY70
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

KYSE-70 is a human esophageal squamous cell carcinoma (ESCC) cell line that is derived from tumor tissue from a Japanese female. The KYSE-70 cell line represents one of the esophageal cancer cell lines in the KYSE series established by Kyoto University's research team. It has adherent growth characteristics in vitro, and a typical epithelial-like or polygonal cell morphology, which demonstrates the features of squamous carcinoma cells such as cobblestone-like appearance.

Molecularly, KYSE-70 has TP53 gene mutation, EGFR expression, and is positive for cytokeratins (CK5/6, CK14) and is usually HPV-negative, which matches the epidemiological characteristics of ESCC in Asian populations. Because of its stable growth characteristics and known genetic background, KYSE-70 is often used in the study of esophageal cancer pathogenesis, drug sensitivity assays, and tumor metastasis model research.

A new NCL-targeting aptamer-drug conjugate as a promising therapy against esophageal cancer

Journal of Nanobiotechnology | DOI | Paper |

Background

Esophageal cancer (EC) is a highly lethal tumor of the digestive system. Nucleolin (NCL) is overexpressed in various tumors and is a potential therapeutic target. In this study, a novel NCL-targeting aptamer-drug conjugate AS1411-HSA-LDP-AE was developed. It consists of the AS1411 aptamer, human serum albumin, leucidomycin de-acylated protein, and an active enediynone chromophore. The results showed that this conjugate could specifically bind and internalize into esophageal cancer cells. It targeted and accumulated in tumors in the xenograft model and exhibited strong cytotoxic activity, inhibition of migration and invasion, induction of apoptosis, and significant in vivo anti-tumor effects. This provides a promising strategy for targeted therapy of esophageal cancer.

Key Findings

This study successfully constructed an aptamer-drug conjugate AS1411-HSA-LDP-AE targeting nucleolin (NCL). NCL is overexpressed in esophageal cancer cells, with the highest expression in KYSE520. AS1411-HSA-LDP can bind to esophageal cancer cells in a concentration-dependent manner and is efficiently internalized. In KYSE520, it mainly undergoes macropinocytosis. In the xenograft model, this conjugate can long-term target and accumulate at the tumor site. AS1411-HSA-LDP-AE strongly inhibits the proliferation of esophageal cancer cells, with the IC50 being the lowest in KYSE520, and it inhibits migration and invasion and induces apoptosis. The apoptotic mechanism involves the mitochondrial pathway: increased ROS, decreased mitochondrial membrane potential, release of cytochrome c, upregulation of Bax, downregulation of Bcl-2, and inhibition of PARP1. In vivo experiments showed that AS1411-HSA-LDP-AE significantly inhibited tumor growth. In the KYSE520 model, the inhibition rates at 0.6 and 1.2 mg/kg doses were 49.9% and 70.1%, respectively, and at 1.6 mg/kg dose in the EC109 model, the inhibition rate was 53.8%. There was no significant toxicity. Immunohistochemistry showed that NCL and Ki-67 were downregulated, and cleaved caspase-3 was upregulated. These results indicate that AS1411-HSA-LDP-AE is a promising targeted therapeutic drug for esophageal cancer.

Contribution

Creative Bioarray offers human esophageal cancer cell lines KYSE520 and KYSE70, which are used for in vitro experiments and the establishment of in vivo xenograft models in this study. The availability of these cell lines is crucial for evaluating the targeting, uptake mechanism and anti-tumor effect of AS1411-HSA-LDP-AE, providing essential material support for the success of the experiments in this study.

Anti-tumor effect of AS1411-HSA-LDP-AE on KYSE520-bearing tumor model.
Fig. 1. Anti-tumor effect of AS1411-HSA-LDP-AE on KYSE520-bearing tumor model.

AMXI-5001 Inhibits both PARP and Microtubule Polymerization

Esophageal cancer is associated with high mortality and poor survival despite standard care. Brand et al. explored the potential of AMXI-5001, a novel dual-action PARP and microtubule polymerization inhibitor, to inhibit esophageal carcinoma growth.

AMXI-5001 has been shown to be an effective inhibitor of parp1/2 and microtubule polymerization. In order to further confirm the mechanism of action in esophageal cancer cells, KYSE-70 cells were treated with AMXI-5001, Olaparib, or Talazoparib for 24 hours. Western blot analysis confirmed that while Olaparib and Talazoparib are capable of PARP inhibition, but not tubulin (Fig. 1A), AMXI-5001 is able to abrogate both PARP and tubulin (Fig. 1A). Furthermore, by immunofluorescence, they confirmed that AMXI-5001 disrupted microtubule networks in a dose dependent manner, while both Olaparib and Talazoparib, do not (Fig. 1C and D). To control for inhibitor and enhancer of microtubule polymerization, they used Vinblastine and paclitaxel, respectively. We conclude that AMXI-5001 can potently inhibit microtubule polymerization in KYSE-70 cells.

AMXI-5001 is a potent inhibitor of PARP and microtubule polymerization.

Fig. 2. AMXI-5001 is a potent inhibitor of PARP and microtubule polymerization (Brand N R, Yang Y W, et al., 2024).

TK-453 Inhibited Cell Proliferation and Induced Apoptosis of Cancer Cells In Vitro

SHP2, encoded by PTPN11, is a non-receptor protein tyrosine phosphatase that has been implicated in a variety of cancers. Dysregulation of SHP2 signaling has been shown to play a role in cancer pathogenesis, and SHP2 is a promising therapeutic target. Tang et al. developed a potent, selective and active SHP2 inhibitor through structure-based design and extensive SAR studies. They also evaluated the impact of SHP2 inhibitors on the proliferation and apoptosis of tumor cells. Hela, KYSE-140 and THP-1 cell lines were selected as paper reported. As shown in Fig. 2A, similar to the control compound SHP099, TK-453 had moderate inhibitory effects on the proliferation of KYSE-70, Hela and THP-1 cells at concentrations of 30 and 100 μM. These findings suggested that these small-molecule compounds might not exert their effects by significantly affecting tumor cell proliferation. TK-453 induced apoptosis in Hela cells in a concentration-dependent manner (Fig. 2B).

Effect of TK-453 on cell proliferation (A) and apoptosis (B).

Fig. 3. Effect of TK-453 on cell proliferation (A) and apoptosis (B) (Tang K, Zhao M, et al., 2022).

Ask a Question

Write your own review

  • You May Also Need

For research use only. Not for any other purpose.

Hot Products